Featured Research

from universities, journals, and other organizations

Giving Smaller Doses Of Chemotherapy More Frequently May Attack Tumor Blood Supply

Date:
March 28, 2001
Source:
Jefferson Medical College
Summary:
Radiation oncologists at Thomas Jefferson University Hospital are rethinking how to give chemotherapy, taking advantage of its unique properties. They are giving chemotherapy more frequently than usual and in tinier doses, targeting the process by which a new blood supply is created feeding tumor growth, called angiogenesis.

Radiation oncologists at Thomas Jefferson University Hospital are rethinking how to give chemotherapy, taking advantage of its unique properties. They are giving chemotherapy more frequently than usual and in tinier doses, targeting the process by which a new blood supply is created feeding tumor growth, called angiogenesis.

Traditionally, most cancer therapies are used in highest possible doses, says Adam Dicker, M.D., Ph.D., assistant professor of radiation oncology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and at Jefferson’s Kimmel Cancer Center. But anti-angiogenesis drugs have caused people to rethink chemotherapy. “Instead of targeting the tumor, perhaps you can target the tumor-associated blood supply,” he says.

Dr. Dicker and his Jefferson co-workers studied the chemotherapy drug docitaxel (Taxotere) in the laboratory in lower-than-usual doses, about one-tenth the clinical dose. They wanted to see the effects of radiation and the drug, which makes cancer cells more vulnerable to radiation, on endothelial cells, which are involved in angiogenesis. They found the lower doses of drug affect different parameters of angiogenesis and can increase the effects with radiation. “This is a unique approach in combination therapy, targeting the vasculature,” Dr. Dicker said.

Dr. Dicker will present the group’s findings March 27 at the annual meeting of the American Association for Cancer Research meeting in New Orleans.

“What’s unique about this is that we’ve used a common chemotherapy agent in an antiangiogenic manner and potentiated that,” Dr. Dicker says. “This area is particularly interesting because these drugs, which are FDA approved, can have antiangiogenic effects.

“It’s a totally new way of thinking, it’s completely changed the paradigm,” says Dr. Dicker. “With all the interest in anti-angiogenesis, you can rethink how you give chemotherapy and radiation.”

According to Dr. Dicker, recent research have shown dramatic effects with conventional chemotherapy, but used in a different way. Instead of using large doses infrequently, every three weeks or so, for example, giving the time the body needs to recover from chemotherapy, preclinical studies have been using lower doses more frequently, maybe twice a week.

They next plan to take this approach, using low-dose docetaxel and radiation therapy, in a study in lung cancer together with colleague Maria Werner-Wasik, M.D., assistant professor of radiation oncology at Jefferson Medical College.


Story Source:

The above story is based on materials provided by Jefferson Medical College. Note: Materials may be edited for content and length.


Cite This Page:

Jefferson Medical College. "Giving Smaller Doses Of Chemotherapy More Frequently May Attack Tumor Blood Supply." ScienceDaily. ScienceDaily, 28 March 2001. <www.sciencedaily.com/releases/2001/03/010328075705.htm>.
Jefferson Medical College. (2001, March 28). Giving Smaller Doses Of Chemotherapy More Frequently May Attack Tumor Blood Supply. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2001/03/010328075705.htm
Jefferson Medical College. "Giving Smaller Doses Of Chemotherapy More Frequently May Attack Tumor Blood Supply." ScienceDaily. www.sciencedaily.com/releases/2001/03/010328075705.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins